Nrf2, Sulforaphane, and Lung Cancer: A Context Problem

Sulforaphane, quercetin, and curcumin can turn on Nrf2, a cellular stress-response program that increases production of antioxidant-defense enzymes. That is the intended point of many "antioxidant" supplement stacks. In former smokers at elevated lung-cancer risk, a Phase II trial found that sulforaphane changed lung-tissue biomarkers in a direction consistent with less proliferation and more programmed cell death. But established lung tumors can also activate NRF2, and higher pathway activity has been associated with worse prognosis.

The apparent contradiction is real, but it does not mean broccoli sprouts cause cancer or that every Nrf2 activator is dangerous. It means biology cares about context. A temporary, regulated response in noncancerous tissue differs from a tumor that has rewired the same pathway to survive.

What Nrf2 does—and what supplements actually do

Nrf2 is a transcription factor. Under ordinary conditions, KEAP1 keeps it restrained in the cell. Electrophilic compounds in foods, including sulforaphane from broccoli sprouts, can modify KEAP1 cysteine residues and allow Nrf2 to enter the nucleus. There it can increase expression of genes such as NQO1 and HMOX1, which help cells manage oxidative and chemical stress.

A 2021 systematic review by Clifford et al. assessed 18 human intervention trials of dietary phytochemicals, including sulforaphane, curcumin, and quercetin. The review concluded that these compounds can activate the Nrf2-ARE pathway at physiologically achievable systemic concentrations, around 1 µmol/L. It also argued that direct free-radical scavenging at those concentrations is unlikely to explain their effects. In other words, the popular "antioxidant" label is too crude: these compounds appear to change cellular signaling rather than simply mop up radicals like a molecular paper towel.

The review also reported conflicting findings across trials. That is not a footnote. Response may vary with dose, duration, tissue type, baseline diet, and genetic variation in KEAP1. A group-average pathway signal does not establish that a given person will respond, or that a larger dose will produce a larger benefit.

The strongest lung-specific prevention signal is a biomarker trial

The most relevant human trial comes from Yuan et al.'s 2025 randomized Phase II trial in former smokers at high risk for lung cancer. Participants received sulforaphane supplementation, and investigators examined lung tissue. Compared with the trial comparator, sulforaphane reduced Ki-67, a marker of cellular proliferation, and increased caspase-3 and TUNEL signals, markers associated with apoptosis.

Those are encouraging biological changes in the population that matters most for this question. They do not show that sulforaphane prevents lung cancer, reduces deaths, or improves screening outcomes. The trial measured surrogate biomarkers rather than cancer incidence, and the published information summarized here does not provide the sample size, effect estimates, confidence intervals, or follow-up details needed to judge the magnitude or precision of the changes. It also did not directly measure Nrf2 protein in lung tissue, so the link from sulforaphane to Nrf2 activation to the observed biomarkers remains a reasonable inference, not direct proof.

Other human studies support the broader claim that plant polyphenols can influence oxidative-stress biology, though they do not answer the lung-cancer question. A 2025 systematic review and meta-analysis of polyphenol-rich interventions reported lower inflammatory and oxidative-stress markers in adults with overweight or obesity. A systematic review of 11 green-tea studies found that regular, but not acute, supplementation improved total antioxidant status and reduced exercise-induced oxidative stress; included interventions used 400 to 800 mg of catechins daily for more than one week. A 2025 meta-analysis in PCOS pooled 15 randomized trials involving 934 participants and reported improvements in oxidative-stress and inflammatory parameters.

These studies involved different populations, interventions, and endpoints. None measured lung-cancer incidence, and none establishes that an antioxidant marker change prevents cancer.

Why established tumors may benefit from the same pathway

The concern shifts once lung cancer exists. A 2025 analysis by Ungvari et al. described NRF2 pathway activation as a predictor of poor prognosis across 2,167 lung-cancer cases. The proposed explanation is biologically plausible: persistent NRF2 activity can increase glutathione synthesis, and glutathione may help tumor cells tolerate oxidative stress and resist platinum chemotherapy.

That finding is observational in humans. It shows an association between a higher NRF2-pathway signature and poorer outcomes; it does not prove that a supplement caused the high pathway activity, caused treatment resistance, or would worsen an individual patient's response. Specific hazard ratios, confidence intervals, survival p-values, and signature details need direct confirmation from the publication before they can support more precise claims.

The distinction between tumor NRF2 activation and dietary induction matters. Cancer cells may acquire persistent pathway activation through somatic alterations involving KEAP1 or NFE2L2, or through abnormal self-reinforcing signaling. Dietary sulforaphane acts through reversible KEAP1 modification. The downstream genes can overlap, but the biological states are not interchangeable.

Still, platinum chemotherapy depends in part on oxidative damage to kill cancer cells. A pathway that raises tumor glutathione is therefore a legitimate concern, especially when laboratory and animal research supports glutathione-linked cisplatin resistance. Human clinical association is not the same as mechanistic proof in patient tumors, but it is enough to make undisclosed supplement use a bad gamble during treatment.

The unanswered dose question

No evidence here identifies a dose at which dietary Nrf2 activation becomes harmful, nor does it show that sustained high-dose supplementation can make premalignant cells behave like tumors with constitutive NRF2 activation. That question has not been answered by the 18-trial review or the former-smoker Phase II study.

It also remains unknown whether people who consume more cruciferous vegetables, or people who take Nrf2-activating supplements, have different lung-cancer incidence or outcomes at population scale. The available evidence cannot settle that.

What to do with the uncertainty

For healthy former smokers, food-level intake of cruciferous vegetables—and dietary-equivalent sulforaphane use—has a plausible mechanistic rationale and a lung-tissue biomarker signal. Call it promising, not proven prevention. There is no human evidence here to justify megadose stacks of sulforaphane, quercetin, and curcumin in pursuit of ever-higher Nrf2 activity.

For anyone with lung cancer, particularly anyone receiving platinum chemotherapy, Nrf2-activating supplements belong on the medication list discussed with the oncology team. The prevention case rests on human intervention studies and surrogate outcomes. The cancer caution rests on a large observational prognosis analysis plus resistance biology that is largely preclinical. Neither side proves more than it proves. But the context-dependent risk is substantial enough that silence is the wrong strategy.